Xue-Qiao Zhao

Xue-Qiao Zhao

Auto-generated profile, based on publicly available information

Xue-Qiao Zhao

Division of Cardiology, Department of Medicine, University of Washington, Seattle, Washington

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2014 in The American Journal of Cardiology
Verified
Journal Article
Closed access
PDF file
XZXue-Qiao Zhao
Xue-Qiao Zhao
THThomas S. Hatsukami
Thomas S. Hatsukami
DHDaniel S. Hippe
Daniel S. Hippe
JSJie Sun
Jie Sun
NBNiranjan Balu
Niranjan Balu
CYChun Yuan
Chun Yuan

1 March 2017 in Journal of Clinical Lipidology
Verified
Journal Article
Open access
XWXing Wu
Xing Wu
ZYZhexin Yu
Zhexin Yu
WSWen Su
Wen Su
DIDaniel A. Isquith
Daniel A. Isquith
MNMoni B. Neradilek
Moni B. Neradilek
XZXue-Qiao Zhao
Xue-Qiao Zhao
Type 2 diabetes mellitus (T2DM) has reported to be a major public health crisis in China. We examined the incidence of new T2DM over 4 years for association of clinical factors and lipids with development of T2DM in a community-based population. We included 923 Chinese subjects who participated in community-organized health checkout in both 2009 and 2013. Health history was collected; physical examination was performed; biochemistry, lipids, and glucose were measured. Of 923, 819 were confirmed without T2DM in 2009 and included in the analysis. Unadjusted and adjusted logistic regression models were used to estimate the effects of clinical factors and biomarkers on the risk of new T2DM. Of 819 subjects without T2DM in 2009, 65 were identified as T2DM in 2013, 8% over 4 years. These 65 subjects, compared with those 754 without new T2DM, were older, more likely to be male and smokers. They had higher body mass index (BMI), fasting glucose, blood pressure and triglycerides, and lower levels of high-density lipoprotein-cholesterol and apolipoprotein A1 (ApoA1). Multivariate logistic regression identified larger BMI (odds ratio [OR] = 1.7; 95% confidence interval [CI], 1.22-2.39, P = .002), higher fasting glucose levels (OR = 4.2, 95% CI, 2.90-6.19, P < .001), and low levels of ApoA1 (OR = 0.51, 95% CI 0.33-0.76, P = .002) were independently associated with new T2DM. Furthermore, receiver operating characteristics curves for multivariate models for new T2DM showed that area under the curve improved from 0.87 to 0.89 when adding ApoA1 to the Framingham Diabetes Risk Scoring Model and from 0.85 to 0.89 when adding ApoA1 to a 4-variable (age, BMI, glucose, and triglycerides) Chinese model. There is a high incidence of new T2DM at 8% over 4 years among Chinese. Larger BMI, higher glucose levels, and lower levels of ApoA1 are significantly and independently associated with new T2DM. Lower ApoA1 improves the risk prediction of new type 2 diabetes when it was added to the existing risk models.

1 March 2018 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
DHDaniel S. Hippe
Daniel S. Hippe
BPBinh An P. Phan
Binh An P. Phan
JSJie Sun
Jie Sun
DIDaniel A. Isquith
Daniel A. Isquith
KOKevin D. O’bRien
Kevin D. O’bRien
XZXue-Qiao Zhao
Xue-Qiao Zhao
Objective—: To assess whether Lp(a) (lipoprotein(a)) levels and other lipid levels were predictive of progression of atherosclerosis burden as assessed by carotid magnetic resonance imaging in subjects who have been treated with LDL-C (low-density lipoprotein cholesterol)–lowering therapy and participated in the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes). Approach and Results—: AIM-HIGH was a randomized, double-blind study of subjects with established vascular disease, elevated triglycerides, and low HDL-C (high-density lipoprotein cholesterol). One hundred fifty-two AIM-HIGH subjects underwent both baseline and 2-year follow-up carotid artery magnetic resonance imaging. Plaque burden was measured by the percent wall volume (%WV) of the carotid artery. Associations between annualized change in %WV with baseline and on-study (1 year) lipid variables were evaluated using multivariate linear regression and the Bonferroni correction to account for multiple comparisons. Average %WV at baseline was 41.6±6.8% and annualized change in %WV over 2 years ranged from −3.2% to 3.7% per year (mean: 0.2±1.1% per year; P =0.032). Increases in %WV were significantly associated with higher baseline Lp(a) (β=0.34 per 1-SD increase of Lp(a); 95% confidence interval, 0.15–0.52; P <0.001) after adjusting for clinical risk factors and other lipid levels. On-study Lp(a) had a similar positive association with %WV progression (β=0.33; 95% confidence interval, 0.15–0.52; P <0.001). Conclusions—: Despite intensive lipid therapy, aimed at aggressively lowering LDL-C to <70 mg/dL, carotid atherosclerosis continued to progress as assessed by carotid magnetic resonance imaging and that elevated Lp(a) levels were independent predictors of increases in atherosclerosis burden.

17 June 2021 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Open access
PDF file
GRGraziella Eliza RONSEIN
Graziella Eliza RONSEIN
TVTomas Vaisar
Tomas Vaisar
WDW. Sean Davidson
W. Sean Davidson
KBKarin E. Bornfeldt
Karin E. Bornfeldt
JPJeffrey L. Probstfield
Jeffrey L. Probstfield
JHJay W. Heinecke
Jay W. Heinecke
Objective: Niacin therapy fails to reduce cardiovascular events in statin-treated subjects even though it increases plasma HDL-C (HDL [high-density lipoprotein] cholesterol) and decreases LDL-C (LDL [low-density lipoprotein] cholesterol) and triglyceride levels. To investigate potential mechanisms for this lack of cardioprotection, we quantified the HDL proteome of subjects in 2 niacin clinical trials: the CPC study (Carotid Plaque Composition) and the HDL Proteomics substudy of the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides).Approach and Results: Using targeted proteomics, we quantified levels of 31 HDL proteins from 124 CPC subjects and 120 AIM-HIGH subjects. The samples were obtained at baseline and after 1 year of statin monotherapy or niacin-statin combination therapy. Compared with statin monotherapy, niacin-statin combination therapy did not reduce HDL-associated apolipoproteins APOC1, APOC2, APOC3, and APOC4, despite significantly lowering triglycerides. In contrast, niacin markedly elevated HDL-associated PLTP (phospholipid transfer protein), CLU (clusterin), and HP/HPR (haptoglobin/haptoglobin-related proteins;P≤0.0001 for each) in both the CPC and AIM-HIGH cohorts.Conclusions: The addition of niacin to statin therapy resulted in elevated levels of multiple HDL proteins linked to increased atherosclerotic risk, which might have compromised the cardioprotective effects associated with higher HDL-C levels and lower levels of LDL-C and triglycerides.Registration: URL:https://www.clinicaltrials.gov; Unique identifier: NCT00715273; NCT00880178; NCT00120289.

1 June 1996 in Circulation
Verified
Journal Article
Closed access
XZXue-Qiao Zhao
Xue-Qiao Zhao
BBB. Greg Brown
B. Greg Brown
DSDouglas K. Stewart
Douglas K. Stewart
LHLynn A. Hillger
Lynn A. Hillger
HBHuiman X. Barnhart
Huiman X. Barnhart
SKSpencer B. King
Spencer B. King
Background The Emory Angioplasty Versus Surgery Trial (EAST) was designed to determine whether percutaneous transluminal coronary angioplasty (PTCA) is as effective as coronary artery bypass graft surgery (CABG) in restoring arterial perfusion capacity in eligible patients with multivessel disease. Methods and Results Of 392 patients in EAST, 198 were randomized to PTCA and 194 to CABG. Index lesions (2.7±1.0 per patient) were those with ≥50% stenosis judged treatable by both angioplasty and surgery. Coronary segments jeopardized by these index lesions were designated as index segments (4.4±1.4 per patient). Percent stenosis was measured by quantitative angiography at the point of greatest obstruction in the main perfusion path of each index segment. The EAST primary arteriographic end point was the percent of a patient’s index segments with <50% stenosis in the main perfusion pathways at 1 and 3 years. At baseline, the percent of index segments for which revascularization was attempted was 85% for PTCA and 98% for CABG ( P <.0001). At 1 year, PTCA patients had a smaller percentage of successfully revascularized index segments than CABG patients (59% versus 88%, P <.001). At 3 years, the findings were similar but less striking (70% versus 87%, P <.001). When only “high-priority” index segments (2.1±1.6 per patient) were considered, baseline attempts were comparable (96% versus 99%, P =NS); despite this, CABG remained more successful at 1 (64% versus 93%, P <.001) and 3 (76% versus 89%, P <.01) years. However, the mean percent of index segments free of severe stenosis (≥70%) did not differ between PTCA and CABG patients at 3 years (93% versus 95%, P =NS). Furthermore, the frequency of patients with all index segments free of severe stenosis did not differ between the two groups at 1 (76% versus 83%, P =NS) or 3 (82% for both PTCA and CABG) years. Conclusions In patients with multivessel disease, index segment revascularization was more complete with CABG than PTCA at both 1 and 3 years. However, when the physiological priority of the target lesion and the measured severity of the residual stenosis are taken into account, the advantage of CABG becomes less significant or nonsignificant. This may, in part, explain why these two strategies did not differ in terms of the EAST primary clinical end points over 3 years.

1 May 2014 in The American Journal of Cardiology
Verified
Journal Article
Closed access
AZAlberto Zambon
Alberto Zambon
XZXue-Qiao Zhao
Xue-Qiao Zhao
BBB. Greg Brown
B. Greg Brown
JBJohn D. Brunzell
John D. Brunzell